Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ThromboGenics Announces Business Update and 2012 Full-Year Results

Published: Tuesday, March 19, 2013
Last Updated: Tuesday, March 19, 2013
Bookmark and Share
Transformational 2012 delivers euro 30 million in net profit.

ThromboGenics NV has issued a business update and its financial results for the full year ending December 31, 2012.

The past 12 months have been a defining period for ThromboGenics, resulting in the approval and launch of its lead drug JETREA® (ocriplasmin) in the US.

US patients and physicians now have access to the first pharmacological treatment for the sight-threatening condition symptomatic vitreomacular adhesion (VMA).

The launch of JETREA® has completed ThromboGenics’ transformation into an integrated company with operations in R&D through to full-scale commercialization.

ThromboGenics expects 2013 to be another crucial year as JETREA® gains more traction in the US and Europe, if approved.

2012 Highlights (including post-period events):
JETREA® (ocriplasmin)

Commercializing JETREA® in the US
• JETREA® was launched in the US on 14 January 2013 after the US Food and Drug Administration (FDA) approved it as the first pharmacological treatment of symptomatic vitreomacular adhesion (VMA)
o Highly focused commercial team, including specialist salesforce, is now working to drive the US sales of JETREA®
o Structure in place to help US physicians process reimbursement claims for JETREA®

Major strategic partnership alliance with Alcon in Europe and ROW
• ThromboGenics entered into a €375 million strategic commercialization agreement with Alcon (Novartis) for the commercialization of ocriplasmin outside the US
o ThromboGenics received €75 million in an upfront payment
o It is eligible for a further €90 million in potential near-term milestone payments, potential further milestones of €210 million, plus additional significant royalties on Alcon’s sales of JETREA® outside the US
o ThromboGenics and Alcon are to share the costs equally of the further development of JETREA®, including new formulations and new indications

• In January 2013, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency granted a positive opinion for JETREA® for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, paving the way for the product’s potential EU approval

Financial
• ThromboGenics raises €77.9 million through a private placement via the issue of 3,244,675 new shares in April 2012
• Positive Belgian tax authority ruling in June 2012 has enabled ThromboGenics to benefit from a “patent income deduction regime” and, therefore, from a reduced tax rate for all patent-related JETREA® income
• €148.2 million in cash and cash investments as of 31 December 2012, compared with €80.4 million at the end of December 2011
• €75.1 million in total revenue in 2012, compared with €2.5 million in 2011
• Net profit of €30.4 million in 2012, equivalent to diluted earnings per share of €0.84. In 2011, the Company reported a net loss of €21.6 million, equivalent to a diluted loss per share of €0.67

Dr Patrik De Haes, CEO of ThromboGenics, said: “The past 12 months have been the most important period in ThromboGenics’ history. The recent launch of JETREA® has completed our transformation into a profitable fully integrated company focused on developing and commercializing innovative ophthalmic medicines. We are delighted that US patients and physicians now have access to JETREA® which is the first pharmacological treatment for symptomatic VMA, an important sight-threatening condition. Initial reactions from retinal physicians and patients to this novel treatment option have been positive and our commercial organization is now focused on building sales of JETREA®.

“Our partnership agreement with Alcon is progressing well and we anticipate gaining EU approval for JETREA® shortly. We are working with Alcon to finalize our reimbursement strategies in the five largest markets in Europe so we are well positioned for the JETREA® launch, which is expected in the first half of 2013. Over the next 12 months we expect to generate further shareholder value as the US sales of JETREA® continue to build and we receive further milestones and the first royalties from Alcon as this novel pharmacological treatment option for symptomatic VMA is commercialized in Europe.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ThromboGenics and VIB Launch New Oncology Company
Oncurious NV to develop TB-403 for pediatric brain tumors.
Tuesday, April 14, 2015
Thrombogenics Awarded €1.1 Million IWT Research Grant
Grant to fund the on-going research to further elucidate the pharmacological effects of ocriplasmin.
Thursday, February 05, 2015
ThromboGenics Appoints Dominique Vanfleteren as New CFO
Dominique has over 25 years of experience in senior finance, operational, control and reporting roles.
Saturday, January 17, 2015
ThromboGenics’ JETREA® Gains First Asian Approval in Malaysia
JETREA® (ocriplasmin) has been approved for the treatment of adults with vitreomacular traction.
Tuesday, April 22, 2014
ThromboGenics Awarded €3 Million IWT Grant
Grant funding to support research new therapeutic for diabetic macular edema.
Tuesday, March 11, 2014
ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA® in the US
ORBIT study designed to generate further data on the “real world” use of JETREA®.
Thursday, March 06, 2014
ThromboGenics’ JETREA® Receives Positive Common Drug Review in Canada
CDR provides formulary listing recommendations to Canada’s publicly funded drug plans.
Monday, December 30, 2013
ThromboGenics Appoints Dr David Guyer to its Board of Directors
Dr Guyer is currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation.
Monday, December 23, 2013
ThromboGenics’ Founder Prof Desire Collen Retiring as Chairman
Dr Staf Van Reet appointed as new Chairman of the Board.
Monday, December 09, 2013
ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics
Collaboration and license agreement to develop and commercialize novel drugs inhibiting a target for DME.
Friday, September 06, 2013
ThromboGenics Licenses Innovative Technology from Eleven Biotherapeutics
Company to develop novel drugs for the treatment of diabetic eye diseases.
Friday, July 05, 2013
ThromboGenics Business Update
US sales through end of April 2013 have exceeded $10 million.
Monday, May 27, 2013
ThromboGenics’ JETREA® Available in Germany Public and Private Market
Company could receive a further €210 million in milestones plus significant royalties.
Friday, May 03, 2013
ThromboGenics Receives Positive CHMP Opinion for JETREA®
Positive opinion clears the way for the potential EMA approval of JETREA® as the first pharmacological option for the treatment of VMT, including when associated with macular hole of diameter less than or equal to 400 microns.
Wednesday, April 24, 2013
ThromboGenics’ JETREA® Granted EU Approval for VMT
EU approval of JETREA® triggers a €45 million milestone payment from Alcon.
Monday, April 15, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!